article thumbnail

Pfizer puts up $1bn to buy into Arvinas breast cancer programme

pharmaphorum

The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for HER2 receptors that would make them candidates for treatment with drugs like trastuzumab. billion in backloaded milestone payments.

Protein 113
article thumbnail

A Complex Chromosomal Abberation Called Adrenoleukodystrophy

Delveinsight

The buildup in adrenal glands leads to the insufficient hormonal response, thus leading to several of the symptoms such as deficiency of steroid hormones (mainly cortisol and aldosterone), impaired cortisol secretion, and others that are harbingers of the disease. A novel, brain penetrant, orally bioavailable and selective PPAR?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Orserdu (elacestrant) Approved for Patients with ESR1 mutations in ER+/HER2- Advanced or Metastatic Breast Cancers

XTalks

Current treatments include hormonal therapies that focus on blocking the function of the estrogen receptor, curbing its production or degrading the receptor itself. Mutations in the ESR1 , however, have contributed to the rise of endocrine resistance. Orserdu is available in the form of 345 mg tablets to be taken once a day with food.

article thumbnail

Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics

Delveinsight

Terns schedules to bring a third candidate into the clinic this year, TERN-501, a thyroid hormone receptor (THR) beta-agonist. The prospects of small molecule binders of RNA over current protein and RNA-based approaches cover potency, selectivity, oral bioavailability, tissue distribution, and central nervous system penetration.

RNA 52